TheraPHIX™,vivoPHIX™, genoPHIX™ and virusPHIX™
Choose a category:
The rapid development of RNA vaccines during the COVID-19 pandemic saved millions of lives. However, one major challenge remains: RNA degrades quickly when exposed to heat, enzymes, or physical stress. This means that current RNA vaccines require deep freezing (-50°C or lower) to remain stable, making global distribution costly and logistically complex.
RNAssist is proud to announce the development of TheraPHIX™, a groundbreaking solution in mRNA vaccine stability. In collaboration with the Centre for Process Innovation (CPI) and with funding from Innovate UK, we have successfully created an ambient temperature liquid-stable mRNA-LNP formulation.
vivoPHIX™ has many applications – wherever your research may take you. Here are some photos from a recent project in South East Asia, where we were collecting bacteria from carnivorous plants. It can be difficult to get the required permits for collecting and transporting samples – whether it be bacteria, seeds or plants.
We are delighted to report that this week RNAssist reagents will be combined with various biological samples aboard the International Space Station
RNAssist technology supports a wide range of life science applications, including tissue fixation and dissociation, single-cell multiomics (scRNA-seq, CITE-seq), and virus inactivation and transport for enhanced diagnostic testing.
Follow us on LinkedIn
© RNAssist | www.RNAssist.com